Prognostic significance of <i>FCGR2B</i> expression for the response of DLBCL patients to rituximab or obinutuzumab treatment
Małgorzata Nowicka(University of Zurich), Mark S. Cragg(University of Southampton), Pedro Farinha, Laura K. Hilton(BC Cancer Agency), Chern Siang Lee(University Hospital Southampton NHS Foundation Trust), David W. Scott(BC Cancer Agency), Farheen Mir(Royal Marsden Hospital), Laurie H. Sehn(BC Cancer Agency), Maurizio Martelli(Sapienza University of Rome), Matthew Carter(University of Southampton), Russell B. Foxall(University of Southampton), Andrea Knapp(Roche (Switzerland)), Jonathan C. Strefford(University of Southampton), Margaret Ashton‐Key(University Hospital Southampton NHS Foundation Trust), Chantal E. Hargreaves(University of Southampton), Matthew Rose‐Zerilli(Southampton General Hospital), Graham W. Slack(BC Cancer Agency), Christian Klein(Roche (Switzerland)), Stephen A. Beers(University of Southampton), Ryan D. Morin(Simon Fraser University), Marek Trněný(Charles University), Christopher R. Bolen(Yale University), Cathy Burton(Leeds Teaching Hospitals NHS Trust), Wolfgang Hiddemann(Christian-Albrechts-Universität zu Kiel), Mikkel Z. Oestergaard(Roche (Switzerland)), Umberto Vitolo(Candiolo Cancer Institute), Kathleen N. Potter(University of Southampton), Christopher Rushton(Simon Fraser University)
Cited by 18
Related Papers
Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
|New England Journal of Medicine|2010|1.3k
A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications
|Cancer Cell|2020|1.1k
A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling
|New England Journal of Medicine|2006|1k